Journal
JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY
Volume 61, Issue 15, Pages 3589-3599Publisher
AMER CHEMICAL SOC
DOI: 10.1021/jf304625x
Keywords
epimedin B; UPLC/Q-TOF-MS; metabolic pathways; metabolites; glucuronic acid conjugation
Funding
- Natural Science Foundation of China [30572372, 30973944, 81274088, 30973978]
- science and technology project fund of Jiangsu Province Bureau of Traditional Chinese Medicine [LZ09067]
- foundation for high-level talent on six areas of Jiangsu province [HZ09032]
Ask authors/readers for more resources
In this work, the metabolite profiles of epimedin B in rat feces, bile, urine, and plasma were qualitatively investigated, and the possible metabolic pathways of epimedin B were subsequently proposed. After oral administration of epimedin B at a single dose of 80 mg/kg, rat biological samples were collected and pretreated by protein precipitation. Then, these pretreated samples were injected into an Acquity ultraperformance liquid chromatography BEH C-18 column with mobile phase consisting of 0.1% formic acid-water and 0.1% formic acid-acetonitrile and detected by ultraperformance liquid chromatography/quadrupole-time-of-flight mass spectrometry. In all, 43 metabolites were identified in the biosamples. Of these, 13, including F5, F7, F16-F18, D5-D7, D9, N5, N7, M1, and M3, were to our knowledge reported for the first time. The results indicated that epimedin B was metabolized via desugarization, dehydrogenation, hydrogenation, hydroxylation, demethylation, glucuronidation, and glycosylation pathways in vivo. Specific hydrolysis of 7-O-glucosides in the gut lumen and glucuronic acid conjugation in the liver were considered as the main physiologic processes of epimedin B. This study revealed the possible metabolite profiles of epimedin B in rats.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available